Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1612 1613 1617 1621 1627 1629
This examiner grants 32% of resolved cases
Gigi Georgiana Huang is an examiner in Tech Center 1600 and Art Unit 1611. The examiner has 610 resolved cases. This substantial record provides a detailed look at the examiner's approach and the likely outcomes for patent applications in this field.
The allowance rate for this examiner is 31.8 percent. This is a relatively low rate, indicating a more difficult path to a grant. However, the interview lift is 30.8 percent. This high lift is a critical piece of information for practitioners, as it shows that interviews are highly effective at improving the chances of success compared to the 31.8 percent baseline. In an environment with a 31.8 percent allowance rate, the 30.8 percent lift is an essential strategy.
The median days to allowance is 1433. This is a longer timeline, reflecting the challenges of prosecution with this examiner. Practitioners should prepare for a process that lasts 1433 days. Given the 31.8 percent allowance rate, the 30.8 percent interview lift should be a central part of any plan to secure a patent in Art Unit 1611.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18721707 | Compositions for providing parenteral nutrition to pediatric patients | Non-Final OA | Fresenius Kabi Deutschland GmbH |
| 18546258 | TREATMENT OF MYOPIA | Non-Final OA | University of Utah Research Foundation |
| 18400940 | PEROXYMONOSULFATE ORAL WHITENING COMPOSITIONS | Non-Final OA | Colgate-Palmolive Company |
| 18775105 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | Non-Final OA | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
| 18917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | Non-Final OA | Oculis Operations Sàrl |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18253096 | EYEDROPS FOR AMELIORATING OR PREVENTING RETINAL CIRCULATION DISORDER AND RETINAL NEUROVASCULAR COUPLING DISORDER | Final Rejection | KINKI UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy